GSK Consumer puts media account in play again, 6 weeks after striking Novartis deal

GSK building
GlaxoSmithKline is reviewing its media agency lineup again, inviting all major advertising holding companies to participate.

The estimated $1 billion media account for GlaxoSmithKline Consumer Healthcare is in play again. The pharma is reviewing its agencies less than three years after its Novartis asset sale-and-swap and just six weeks after GSK agreed to buy Novartis' remaining share in the pair's OTC venture to take full ownership of the business.

At the time of the asset swap and partnership in 2015, GSK did a review and consolidated with its two incumbent agencies, Omnicom's PHD and WPP’s Mediacom. Those two, however, now seem to be on notice, with all six major ad networks invited to pitch, Adweek reports, opening up to Publicis, Dentsu, Havas and IPG. PHD currently handles North American duties for GSK, while Mediacom handles the overseas work.

The payoff for the winner (or winners) is potentially huge: GSK spent more than $1 billion on media in 2017, Adweek notes. But the British drugmaker isn’t showing its hand, noting in a statement to FiercePharma only that, “GSK periodically reviews its media buying arrangements to ensure they are continuing to deliver the best value to the business.”


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

RELATED: MLB All-Star Justin Verlander joins pitch for GSK allergy med Flonase

While this review seems consistent with its every-three-year process, the last review in 2015 came on the heels of the multibillion-dollar shuffle in which GSK exchanged its cancer portfolio for most of Novartis' vaccines.

GSK Consumer Healthcare then operated as a joint venture between the two pharmas until recently, with GSK as the managing partner and the larger stakeholder at 63.5%. In March, GSK agreed to buyout Novartis’ 36.5% stake for $13 billion. Just days before the announcement, GSK dropped out of bidding for Pfizer’s OTC assets.

RELATED: Bayer, GlaxoSmithKline find consumer health is not the sure safe haven they expected

Consumer Healthcare is one of GSK’s three main divisions, along with Pharma and Vaccines. It is the second-largest division after pharma, accounting for sales of £7.8 billion of the company’s total £30.2 billion revenue in 2017. CEO Emma Walmsley is the former head of the consumer business, which is now headed by Brian McNamara.

Suggested Articles

Eli Lilly and Boehringer's Jardiance fell short in a heart failure trial in patients with or without diabetes—a test AZ's rival Farxiga recently aced.

There's a lot at stake in the world of pharma litigation, and in two cases involving J&J and Gilead, attorney misconduct allegations have come up.

Without any new data, Sarepta appealed an FDA rejection and got a surprising nod for Vyondys 53—its second med approved on a surrogate marker.